GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
1-Year Est. Return
49.13%
1 Year Est. Return
+49.13%
AUM
$276M
AUM Growth
-$11.6M
(-4%)
Holding
70
Top Buys
| 1 | +$13.1M | |
| 2 | +$9.25M | |
| 3 | +$8.12M | |
| 4 |
Janux Therapeutics
JANX
|
+$6.36M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$5.2M |
Top Sells
| 1 | +$17M | |
| 2 | +$11.7M | |
| 3 | +$8.65M | |
| 4 |
Vaxcyte
PCVX
|
+$8M |
| 5 |
Soleno Therapeutics
SLNO
|
+$7.57M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Sarepta Therapeutics
SRPT
$2.17B
| $15M | 4.53% |
120,000
+65,000
|
|
||
2
Novo Nordisk
NVO
$220B
| $13.1M | 3.96% |
+110,000
|
|
||
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $12.9M | 3.91% |
140,000
+100,000
|
|
||
4
Axsome Therapeutics
AXSM
$7.62B
| $12.1M | 3.66% |
135,000
-15,000
|
|
||
5
Tarsus Pharmaceuticals
TARS
$3.4B
| $11.5M | 3.48% |
350,000
+115,000
|
|
||
6
Perspective Therapeutics
CATX
$169M
| $10M | 3.02% |
750,000
-175,000
|
|
||
7
CG Oncology
CGON
$3.6B
| $9.43M | 2.85% |
250,000
-10,000
|
|
||
8
Roivant Sciences
ROIV
$14.4B
| $9.23M | 2.79% |
800,000
-200,000
|
|
||
|
9
Vaxcyte
PCVX
$6.05B
| $9.14M | 2.76% |
80,000
-70,000
|
|
||
10
Viking Therapeutics
VKTX
$4.05B
| $8.86M | 2.68% |
140,000
+45,000
|
|
||
11
Syndax Pharmaceuticals
SNDX
$1.72B
| $8.66M | 2.62% |
450,000
+100,000
|
|
||
|
12
Janux Therapeutics
JANX
$2.01B
| $8.63M | 2.61% |
190,000
+140,000
|
|
||
13
Ascendis Pharma
ASND
$13B
| $7.84M | 2.37% |
52,500
-34,221
|
|
||
14
Crinetics Pharmaceuticals
CRNX
$4.29B
| $7.67M | 2.32% |
150,000
-90,000
|
|
||
|
15
Soleno Therapeutics
SLNO
$2.66B
| $7.57M | 2.29% |
150,000
-150,000
|
|
||
16
TG Therapeutics
TGTX
$5.1B
| $7.25M | 2.19% |
310,000
-190,000
|
|
||
17
Rezolute
RZLT
$875M
| $7.15M | 2.16% |
1,474,995
+53,494
|
|
||
18
Phathom Pharmaceuticals
PHAT
$1.07B
| $6.78M | 2.05% |
375,000
-225,000
|
|
||
19
MoonLake Immunotherapeutics
MLTX
$964M
| $6.47M | 1.96% |
128,411
-171,589
|
|
||
20
Olema Pharmaceuticals
OLMA
$2.25B
| $6.39M | 1.93% |
535,000
-15,000
|
|
||
21
Immunovant
IMVT
$4.22B
| $6.13M | 1.85% |
215,000
-45,000
|
|
||
22
Insmed
INSM
$44.1B
| $5.47M | 1.65% |
75,000
+10,000
|
|
||
|
23
Edgewise Therapeutics
EWTX
$2.75B
| $5.2M | 1.57% |
+195,000
|
|
||
24
Replimune Group
REPL
$788M
| $4.93M | 1.49% |
450,000
|
|
||
25
BridgeBio Pharma
BBIO
$13.9B
| $4.46M | 1.35% |
175,000
+35,000
|
|